View Clinical Trial (Medical Research Study)

Bone Health in Type 1 Diabetes - NCT00651196-68131(Clinical Trial 212774)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Omaha
State:  
NE
Zip Code: 68131
Conditions: Type 1 Diabetes - Osteoporosis
Purpose: An increased skeletal fracture risk in diabetes has only recently been recognized. This human study is designed to elucidate the effect of Type 1 diabetes on bone remodeling and on structure.
Study summary: An increased skeletal fracture risk in diabetes has only recently been recognized. Human studies of patients with diabetes using bone mineral density and bone markers have noted low bone mass and mixed results on remodeling activity. Mouse models of diabetes have suggested that low bone turnover is the underlying problem. Low bone turnover could lead to an accumulation of microdamage that is not repaired causing compromised bone strength. Low bone turnover has not yet been confirmed in humans. This human study is designed to elucidate the effect of Type 1 diabetes on 1) bone remodeling, including histomorphometric and biochemical measures of bone formation and resorption, and 2) on structure, including micro architectural arrangement of trabeculae and bone mineral density.
Criteria: Inclusion Criteria: - Age > 19 yrs or < 50 yrs. - The diabetic subjects must have a diagnosis of Type 1 diabetes clinically defined as diabetes onset before age 50, acute presentation or diabetic ketoacidosis, with normal BMI. If history is equivocal, GAD antibodies > 1.45 U/mL will be used to define diagnosis. - Diabetic subjects must be on insulin treatment. - All subjects must have BMI between 18-30 Exclusion Criteria: - On any medications that are known to interfere with bone metabolism including loop diuretics, steroids, anticonvulsants, bisphosphonates, metformin, glitazones - Have normal or only mildly impaired kidney function defined as a calculated GFR greater than 60 mL/min/1.73m2 - History of cancer other than skin cancer - Unstable angina, myocardial infarction, uncontrolled hypertension, malabsorption, active rheumatoid or collagen disease.
Study is available at: Creighton University
Omaha, NE 68131
United States

Primary Contact:
Julie Stubby, RN
Email: jstubby@creighton.edu
Phone: 402-280-4958

Secondary Contact:
Julie Stubby, RN
Email: jas@creighton.edu
Phone: 402-280-4958
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.